Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Upreti

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Proteomics|January 5, 2011
Increased oxidative-modifications of cytosolic proteins in 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-exposed rat liverVijay V Upreti, Kwan-Hoon Moon, Li-Rong Yu, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspectiveH M Jones, Y Chen, C Gibson, et al.
Leukemia|April 23, 2020
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myelomaHans C Lee, Noopur S Raje, Ola Landgren, et al.
Journal for Immunotherapy of Cancer|September 27, 2018
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsBen Tran, Richard D Carvajal, Aurelien Marabelle, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 23, 2009
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogenZeynep S Teksin, Insong J Lee, Noble N Nemieboka, et al.
Clinical Drug Investigation|April 4, 2013
Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjectsVijay V Upreti, Chi-Fung Keung, David W Boulton, et al.
Journal of Clinical Pharmacology|June 17, 2004
Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation studyArani Chatterjee, Raghunadharao Digumarti, Rao N V S Mamidi, et al.
Journal of Clinical Pharmacology|March 22, 2005
Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I studyArani Chatterjee, Raghunadharao Digumarti, Kasiram Katneni, et al.
Journal of Clinical Pharmacology|April 24, 2026
A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on HemodialysisCaroline Mohrmann, Rajneet K Oberoi, Stephen D Flach, et al.
Clinical Pharmacology and Therapeutics|July 2, 2023
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry PerspectiveHardik Mody, Ken Ogasawara, Xu Zhu, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Proteomics|January 5, 2011
Increased oxidative-modifications of cytosolic proteins in 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-exposed rat liverVijay V Upreti, Kwan-Hoon Moon, Li-Rong Yu, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspectiveH M Jones, Y Chen, C Gibson, et al.
Leukemia|April 23, 2020
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myelomaHans C Lee, Noopur S Raje, Ola Landgren, et al.
Journal for Immunotherapy of Cancer|September 27, 2018
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsBen Tran, Richard D Carvajal, Aurelien Marabelle, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 23, 2009
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogenZeynep S Teksin, Insong J Lee, Noble N Nemieboka, et al.
Clinical Drug Investigation|April 4, 2013
Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjectsVijay V Upreti, Chi-Fung Keung, David W Boulton, et al.
Journal of Clinical Pharmacology|June 17, 2004
Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation studyArani Chatterjee, Raghunadharao Digumarti, Rao N V S Mamidi, et al.
Journal of Clinical Pharmacology|March 22, 2005
Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I studyArani Chatterjee, Raghunadharao Digumarti, Kasiram Katneni, et al.
Journal of Clinical Pharmacology|April 24, 2026
A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on HemodialysisCaroline Mohrmann, Rajneet K Oberoi, Stephen D Flach, et al.
Clinical Pharmacology and Therapeutics|July 2, 2023
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry PerspectiveHardik Mody, Ken Ogasawara, Xu Zhu, et al.
Pageof 7